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Introduction
New therapies have dramatically changed the way both
clinicians and patients think about treatment of rheumatoid
arthritis (RA). Indeed, it has become realistic to think about
improvement defined by the ACR70 (reduction by 70% in
the American College of Rheumatology composite
response criteria) as the standard of care, and even to
consider the possibility of remission and prevention of
long-term disability. However, the possibility of cure
remains remote. Why we do not have a cure for RA is a
question that patients around the world continue to ask
their physicians daily but, unfortunately, is no better
answered in this millennium than it was in the last.
Rheumatologists, the eternal optimists, can now offer their
patients confident reassurance that the tragic outcomes of
past decades are largely preventable, albeit at consider-
able ongoing expense. Yet the very fact that chronic, and
generally uninterrupted, therapy is needed to suppress the
manifestations of this disease is perhaps the clearest indi-
cation that a cure is nowhere in sight. Indeed, finding a
cure for established RA is possibly no more likely than
finding a cure for hypertension, where control of organ
damage is the only realistic goal of therapy. The impedi-
ments we currently face in finding a cure for RA are
numerous and are considered here. They are summarized
in Table 1. In addition, the possibility that RA can be pre-
vented is explored.
Is there a well-defined etiology for RA?
It is hard to find a cure for RA when the cause is unknown.
Considerable attention has focused on the possibility that
there is an infectious etiology of RA. Most would, however,
agree that the possibility of finding a single infectious etiol-
ogy for this disorder has been all but eliminated. Yet the
modest success achieved by the use of minocycline in the
treatment of RA continues to be interpreted by some as
being indicative of a bacterial etiology that has completely
eluded detection by the scientific community. Proponents
of this hypothesis have been particularly vocal and visible
to the lay community at large. A viral etiology has been
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even more difficult to disprove. Perhaps the strongest
case has been made for parvovirus B19 and retroviruses.
However, recent findings identifying parvovirus-B19
nucleic acid and antigens in a high proportion of RA syn-
ovial tissue samples and not in samples of non-RA synovium
have not been replicated [1]. The synovial detection of this
ubiquitous agent is probably related to the presence of
inflammation rather than the cause of it. The RA-like
lentivirus arthropathy that affects goats has stimulated inter-
est in a retroviral etiology for the human disease. Studies
demonstrating the presence of unique retroviral sequences
in genomic material from RA synovial tissues and cells have
also been difficult to reproduce [2,3]. Even if a retroviral eti-
ology were to be discovered, the lessons learned from HIV
would suggest that the discovery would be unlikely to lead
to a cure or a vaccine in the foreseeable future.
If microorganisms are involved in the pathogenesis of at
least some cases of RA, it is more likely in an indirect role,
such as contributing to the development of autoimmunity
through mechanisms such as molecular mimicry. A per-
suasive case has been made for immune responses to
endogenous heat shock proteins that have been shown to
share sequences with those of a number of microorgan-
isms [4]. One of the microorganisms incriminated is
Escherichia coli, a ubiquitous part of the gastrointestinal
flora. Intriguingly, these sequences are also present in the
HLA-DR4 alleles that are associated with RA [5]. If gut
bacteria are indeed involved in precipitating immune
responses to endogenous antigens, the elimination of
such etiologic agents is obviously not a realistic goal.
More viable approaches might be specific immunomodula-
tion using strategies such as oral tolerization, induction of
T-regulatory cells, or redirection of T-cell function.
It is now widely believed that the first event in RA may be
nonspecific inflammation, which leads to T-cell priming in
genetically susceptible individuals as a secondary event,
this serving to accentuate and amplify the inflammation.
This paradigm is shown in Fig. 1. An alternative hypothesis
suggests that autoimmunity is primary in RA, and that
autoimmune mechanisms precipitate and sustain the
disease. Yet the identification of RA specific autoantigens
has been elusive. The most logical place to look for
autoantigens is in the joint itself. Antigens derived from car-
tilage are particularly intriguing candidates. Because of its
established role in precipitating a destructive, RA-like
arthropathy in susceptible mice, type II collagen has been
the most thoroughly studied antigen. The adoptive transfer
of murine collagen-induced arthritis using T cells and anti-
bodies has suggested that immune responses to this artic-
ular antigen are likely to be of relevance in human RA. Yet
extensive studies in RA patients have failed to confirm this
hypothesis. Indeed, detailed analyses of T-cell receptor
repertoire in RA do not consistently demonstrate evidence
of any oligoclonal bias, and when present, the patterns
differ from patient to patient. It has been suggested that
there may be a global defect in generating a diverse T-cell
repertoire in patients with RA, and that this may be a
primary defect rather than a result of the disease [6].
Recently, there has been a resurgence of interest in the
potential role of autoantibodies in the pathogenesis of RA.
Although rheumatoid factor has long been the hallmark of
this disease, it has been difficult to incriminate this auto-
antibody directly in the pathogenesis of either the synovitis
or the resultant articular damage. The demonstration that
there are other autoantibodies with a higher degree of
specificity for RA than that of rheumatoid factor has given
Table 1
Obstacles to curing RA
Lack of knowledge of etiology
Incomplete understanding of pathogenesis
Lack of means to intervene in most of the relevant processes
Disease heterogeneity
Inability to make an early diagnosis
Limited ability to recognize those at risk
Figure 1
A current paradigm for the pathogenesis of rheumatoid arthritis that
does not require an immune-recognition event of arthritogenic antigens
at the induction phase. In this paradigm, nonspecific inflammation from
a variety of causes precipitates an aberrant synovial response in a
genetically susceptible individual. Subsequent recruitment of immune
cells, including B cells, T cells, and dendritic cells, establishes an
ectopic lymphoid organ in the synovium that facilitates the local
production of autoantibodies to synovial constituents. Autoantibodies,
along with activated T cells, serve to amplify the inflammation and the
consequent tissue damage. Such a nonspecific onset for the disease
is in keeping with the observed heterogeneity in clinical, pathological,
and immunological features of RA.
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new impetus to the attempts to identify their correspond-
ing autoantigens [7]. In particular, it has been shown that
reactivity to citrulline, a residue generated by the post-trans-
lational modification of arginine, is critical to a number of the
autoantibody responses specific to RA [8]. Whether these
antibodies are directed towards a specific articular antigen
remains to be seen. In contrast, the need to implicate an
antigen specific to joints has recently been challenged by a
murine serum-transfer model, in which a ubiquitous cyto-
plasmic protein, glucose-6-phosphate isomerase (GPI), is
the target antigen [9]. Very recent studies suggest that this
enzyme of the Krebs cycle is abundant on the surface of the
articular cartilage in affected animals [10]. Although anti-
GPI antibodies have been detected in patients with inflam-
matory arthritis, RA specificity remains controversial.
Another issue that may influence the capacity to induce
remission in RA patients is the considerable heterogeneity
of the disease. The clinical, pathological, and immunologi-
cal heterogeneity seen in this disorder has been well doc-
umented. Yet the underlying basis of this heterogeneity is
not well understood. This may well be indicative of the
presence of multiple pathogenic factors, operating individ-
ually or in combination, in genetically susceptible individu-
als. Moreover, it is clear that the underlying genetic
susceptibility itself may be heterogeneous in different pop-
ulations. Thus, RA may not be a single disease entity with
a well-defined etiology that has yet to be identified, but
rather a characteristic clinical syndrome resulting from a
complex, and possibly cumulative, interaction of multiple
environmental and genetic factors.
Can RA be ‘cured’ once persistent synovitis is
established?
There are now highly effective therapies for RA. Control of
systemic and articular inflammation, along with significant
retardation of articular damage, are becoming the norm in
all but the most resistant patients. This will almost certainly
translate into long-term prevention of disability as patients
are aggressively treated early in their disease course. Yet
the available arsenal of RA therapies rarely, if ever,
induces a lasting, drug-free remission in the disease, in
other words something akin to a cure. Indeed, there is an
almost predictable, often severe, relapse associated with
the withdrawal of most of the ‘disease-modifying’
antirheumatic drugs currently used in clinical practice,
including biologic agents that target tumor necrosis factor
(TNF)-α and IL-1. The exceptions to this phenomenon,
observed occasionally in some individuals having taken
antimalarials and injectable gold salts, most likely relate to
the long tissue half-life of these agents rather than an
intrinsic ability to induce sustained remissions.
The most plausible explanation for the phenomenon of
relapse after withdrawal of antirheumatic drugs is that these
therapies are collectively aimed at suppressing relatively
peripheral pathways of inflammation and not central abnor-
malities in cell function that underlie the disease. What are
some potential candidates for such central abnormalities?
There is clearly a wide divergence of opinion regarding the
answer to this question. Proponents of the central and
primary role of autoimmunity in the pathogenesis of RA con-
clude that autoantigens, either in intra-articular or extra-artic-
ular locations, will invariably reignite inflammation when the
effects of suppressive therapy are withdrawn. Even a rela-
tively complete ‘overhaul’ of the immune system, as
achieved by bone marrow transplantation, has been associ-
ated with recurrence of disease, albeit in milder form, pre-
sumably because disease-specific memory cells are not
adequately deleted by these procedures. Proponents of an
occult infectious etiology conclude that recurrence of
disease is inevitable if the offending agent is not specifically
eradicated. Finally, mechanical abnormalities in the joints
induced by antecedent inflammation may predispose to
subsequent inflammation whenever anti-inflammatory treat-
ments are withdrawn.
A hypothesis that is currently gaining momentum suggests
that RA patients may have intrinsic abnormalities in their
synovial responses to inflammation and injury, irrespective
of the cause. The inability to bring these responses to res-
olution effectively may lead to the persistence of an
aggressive, angiogenic granulation tissue that is highly
equipped to reinduce inflammation and remodel the sur-
rounding articular structures. It has been suggested that
the primary effectors of this aberrant response are
macrophages, osteoclasts, and fibroblasts.
Macrophages and their products, particularly TNF-α, are
responsible for many of the inflammatory manifestations of
the synovial lesion, including the activation of the synovial
endothelium, which results in the ongoing recruitment of
other classes of leukocytes. The dramatic and rapid anti-
inflammatory effect associated with the inhibition of TNF-α
is compelling evidence for its central role in regulating this
inflammatory process. Yet, as mentioned above, the almost
predictable recurrence of the inflammation with the with-
drawal of this therapy clearly indicates that this effector
pathway is rapidly reinitiated by more central mechanisms.
Recent evidence suggests that osteoclasts are likely to be
the primary effectors of the bone erosions that are typical
of RA [11]. Osteoclastogenesis and bone resorption
occur from the outside in, i.e. from the synovial pannus
into the marginal bone, and from the inside out, i.e. from
the subchondral bone out to the bone surface. The impor-
tance of the subchondral bone and bone marrow in the
pathogenesis of rheumatoid articular damage is becoming
increasingly recognized. Strategies targeting osteoclasts
and osteoclastogenesis are quite promising as regards
preventing erosive damage, even in the absence of associ-
ated anti-inflammatory effects [12]. Indeed, the impressive
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effects of anti-TNF agents in retarding the progression of
erosive damage may well be related to their direct effects
on osteoclast formation and/or function rather than their
effects on inflammation [13]. Is this bringing us closer to a
cure? Most would agree that effective prevention of tissue
damage is a major step forward, but that the need to
sustain therapy to achieve this cannot be equated with a
cure, in which the entire inflammatory/proliferative/
destructive process is brought to a complete and sus-
tained resolution. In this latter scenario, although a relapse
may still be possible, as it is in the case of tumors and
chronic infections, there would be no need for ongoing
therapy unless such a relapse did indeed occur.
In contrast to the erosive bone damage, damage to the
articular cartilage in RA appears to be mediated by synovial
fibroblast-like cells and chondrocytes. ‘Transformed’ syn-
ovial fibroblasts invade articular cartilage by degrading the
extracellular matrix of the cartilage through the production
of a variety of proteases. Additionally, under the influence
of proinflammatory cytokines, particularly IL-1, chondro-
cytes become major participants in the degradation of the
surrounding cartilage matrix, while losing their capacity to
repair the damage by synthesizing new matrix components.
Inhibiting the effects of IL-1 by changing the balance
between this cytokine and its physiological inhibitor IL-1Ra
has proven to be an effective strategy in preventing articu-
lar damage. Ultimately, because of the avascular nature of
cartilage, once damage has occurred, it cannot be
repaired, thus making a cure essentially impossible.
It appears that once the inflammatory rheumatoid synovial
organ has formed in a specific joint, it is unlikely that this
tissue can be brought back to ‘normal’. Moreover, the
process almost certainly begins before there are clinical
signs, and by the time the disease becomes clinically
evident, in most cases the synovitis is capable of
autonomous perpetuation. Therefore, by the time clinicians
perceive that the disease is even present, a cure may have
already become very difficult to achieve.
Can RA be prevented before synovitis
becomes clinically evident?
One of the major impediments to the development of
definitive treatment for RA is the inability to detect, and in
turn study, the earliest events that predictably lead to the
development of persistent, destructive synovitis. There are
virtually no data, epidemiologic or otherwise, regarding the
premorbid status of individuals destined to develop RA. It
can reasonably be asked: can anyone develop RA given
the right circumstances? The available data indicate that a
typical high-risk individual would be a perimenopausal
woman with a family history of RA or a related autoimmune
disease, who is a smoker, who is positive for rheumatoid
factor, and who carries at least one HLA-DR4 allele. The
risk of such an individual developing clinically detectable
disease, say, within 5 years, has not been established. A
conservative estimate would be at least 5% and the actual
risk could be substantially higher. Assembling and longitu-
dinally studying a cohort of such individuals would afford
the best opportunity to understand how RA starts and, ulti-
mately, how it can be prevented.
If such a ‘pre-RA’ cohort were to be assembled, early indi-
cators of impending clinical disease would need to be
sought in a longitudinal study. Particular attention would
be paid to aspects such as the development of specific
autoantibodies. Such a strategy has been used effectively
to predict the onset of autoimmune diabetes in genetically
susceptible children [14]. Although this latter disorder has
a more predictable age of onset, thus lending itself better
to this type of strategy, a similar approach might be
adopted with certain populations of individuals that are at
high risk for developing RA. Longitudinal analysis of serum
to detect the development of specific autoantibodies may
ultimately be too restrictive an approach, and the applica-
tion of broad-based proteomic approaches may be neces-
sary to identify novel and unsuspected markers.
An important aspect of studying the early stages of RA
would be the longitudinal examination of typical ‘RA joints’
such as the knees and MCPs using sensitive imaging
modalities such as MRI, PET, or spectroscopy. The avail-
able histopathologic studies of clinically uninvolved joints
have demonstrated the presence of subclinical synovitis in
affected individuals [15,16]. This can broadly be taken to
imply that there is likely an early, subclinical stage in the
history of each RA patient in which the synovium becomes
abnormal without actually being clinically inflamed. During
this initiation stage, it may be possible to prevent the traf-
ficking of specific cells into the synovial microevironment,
thereby averting the deleterious downstream events that
result once these cells provoke aberrant synovial
responses. In particular, inhibiting the recruitment of T cells
and dendritic cells would be a logical objective. A poten-
tially appealing strategy involves the use of chemokine
inhibitors. The inhibition of candidate chemokines such as
stromal derived factor-1 (CXCL12), which is an important
mechanism by which stromal cells recruit lymphocytes, has
been shown to be quite effective in animal models [17].
Alternatively, strategies that serve to bias the immune
system away from Th1 responses towards Th2 responses
may also prove to be effective in preventing the disease,
although there has been a suggestion that patients with RA
may have defects in Th2 differentiation [18]. The key would
be the detection of early events, before the establishment
of the chronic inflammatory synovial organ.
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